ArticleJournal of virology2018
Improvement of the Dengue Virus (DENV) Nonhuman Primate Model via a Reverse Translational Approach Based on Dengue Vaccine Clinical Efficacy Data against DENV-2 and -4.
Article in Journal of virology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 19 citations in OpenAlex.
- Dengue vaccine breakthrough infections reveal properties of neutralizing antibodies linked to protection.The Journal of clinical investigation · 2021Trial
- Safety and Immunogenicity of an AS03The American journal of tropical medicine and hygiene · 2020Trial
- Rethinking non-human primate models for emerging viral infections after COVID-19.Laboratory animal research · 2026Review
- Dengue vaccines: The role of a correlate of protection in evaluating vaccine safety and risk.Vaccine · 2026Article
- Safety of a tetravalent live dengue virus vaccine in children responding to one serotype only.JCI insight · 2026Article
- Multivalent administration of dengue E dimers on liposomes elicits type-specific neutralizing responses without immune interference.NPJ vaccines · 2025Article
- Current status of the development of dengue vaccines.Vaccine: X · 2025Review
- Dengue virus: pathogenesis and potential for small molecule inhibitors.Bioscience reports · 2024Review
- A live dengue virus vaccine carrying a chimeric envelope glycoprotein elicits dual DENV2-DENV4 serotype-specific immunity.Nature communications · 2023Article
- A multiple-target mRNA-LNP vaccine induces protective immunity against experimental multi-serotype DENV in mice.Virologica Sinica · 2022Article
- Vaccine-induced antibodies to contemporary strains of dengue virus type 4 show a mechanistic correlate of protective immunity.Cell reports · 2022Article
- Mammalian animal models for dengue virus infection: a recent overview.Archives of virology · 2022Review
- Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003).PLoS neglected tropical diseases · 2021Article
- Route of inoculation and mosquito vector exposure modulate dengue virus replication kinetics and immune responses in rhesus macaques.PLoS neglected tropical diseases · 2020Article
- Detection of post-vaccination enhanced dengue virus infection in macaques: An improved model for early assessment of dengue vaccines.PLoS pathogens · 2019Article
- A review of Dengvaxia®: development to deployment.Human vaccines & immunotherapeutics · 2019Review
- Dengue: a growing threat requiring vaccine development for disease prevention.Pathogens and global health · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent data obtained with the live-attenuated tetravalent dengue CYD-TDV vaccine showed higher protective efficacy against dengue virus type 4 (DENV-4) than against DENV-2. In contrast, results from previous studies in nonhuman primates predicted comparable high levels of protection against each serotype. Maximum viral loads achieved in macaques by subcutaneous inoculation of DENV are generally much lower than those observed in naturally dengue virus-infected humans. This may contribute to an overestimation of vaccine efficacy. Using more-stringent DENV infection conditions consisting of the intravenous inoculation of 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.